WO1996040087A2 - Pressure sensitive acrylate adhesive composition cross-linked with aluminum acetylacetonate and containing a drug having a reactive aromatic hydroxyl group - Google Patents
Pressure sensitive acrylate adhesive composition cross-linked with aluminum acetylacetonate and containing a drug having a reactive aromatic hydroxyl group Download PDFInfo
- Publication number
- WO1996040087A2 WO1996040087A2 PCT/US1996/008492 US9608492W WO9640087A2 WO 1996040087 A2 WO1996040087 A2 WO 1996040087A2 US 9608492 W US9608492 W US 9608492W WO 9640087 A2 WO9640087 A2 WO 9640087A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drug
- composition
- patch
- aluminum acetylacetonate
- estradiol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
Definitions
- the present invention relates to transdermal drug delivery patches. More particularly it concerns a matrix type transdermal drug delivery patch whose matrix comprises a mixture of a pressure sensitive acrylate adhesive crosslinked with aluminum acetylacetonate and a drug, such as estradiol, which has a reactive aromatic hydroxyl group.
- Transdermal drug delivery patches normally include a backing layer that forms the outer face of the patch, a drug reservoir underlying the backing layer, and means to affix the patch to the skin.
- the drug reservoir may be a liquid solution or suspension of the drug or a solid matrix of a drug-carrier mixture.
- the carrier of the solid matrix may be an adhesive or have nonadhesive properties. If it is adhesive, the matrix may serve as the means for affixing the patch to the skin. If it is not adhesive, an in-line adhesive layer may underlie the matrix for affixing the patch to the skin.
- the reservoir is a liquid, the patch will often include a drug-permeable membrane that underlies the reservoir and an in-line adhesive layer that underlies the membrane.
- Pressure sensitive adhesives are often used as the adhesive in the above- described patches. Pressure sensitive adhesives are used either as the carrier of the drug-containing matrix or as a separate in-line adhesive layer. In either instance the pressure sensitive adhesive will be admixed with drug.
- Solution polyacrylate adhesives are one type of pressure sensitive adhesive that are used in transdermal drug delivery patches. Solution polyacrylates are made by copolymerizing one or more acrylate monomers, a modifying monomer and a monomer containing functional groups in a solution of an organic solvent. 2-Ethylhexylacrylate, butylacrylate and isooctylacrylate are commonly used as the acrylate monomer. The polyacrylate may be crosslinked on uncrosslinked.
- Crosslinked acrylate adhesives generally have better cohesive strength and resistance to cold flow than uncrosslinked acrylate adhesives. Increased cohesive strength is desirable in transdermal uses of acrylates to reduce the mass transfer of adhesive to the skin when the patch is removed. Resistance to cold flow is desirable to prevent the adhesive from oozing from the patch during storage or wear. Accordingly, crosslinked solution polyacrylates are preferred.
- U.S. 5,393,529 describes an adhesive matrix type transdermal patch for delivering estradiol or estradiol esters.
- the adhesive of the matrix may be a crosslinked or uncrosslinked solution polyacrylate containing a water-swellable polymer.
- Aluminum acetylacetonate is included in a list of possible agents for crosslinking the polyacrylate.
- U.S. 5,292,951 describes estrogen-containing gels for topical application.
- the gels are comprised of estrogen, crosslinked acrylate polymers and relatively large amounts of a fat or oil that serves as an estrogen solubilizer.
- the present invention provides an adhesive composition comprising a crosslinked pressure sensitive acrylate adhesive mixed with an aromatic hydroxy-containing drug that does not develop objectionable color and has good cohesive strength and cold flow properties. Disclosure of the Invention
- One aspect of the invention is a pressure sensitive adhesive composition useful in a transdermal drug delivery patch comprising a mixture of: a) a drug having a reactive aromatic hydroxyl group; and b) an aluminum acetylacetonate crosslinked solution polyacrylate pressure sensitive adhesive.
- transdermal drug delivery patch in the form of a laminated composite comprising:
- a backing layer that forms the top surface of the patch (a) a backing layer that forms the top surface of the patch; and (b) a matrix layer underlying the backing layer that comprises:
- the pressure sensitive adhesive component of the invention compositions and patches is a solution polyacrylate.
- Such polyacrylates are made by copolymerizing one or more main acrylate monomers ("acrylate” is intended to include both acrylates and methacrylates), one or more modifying monomers, and one or more functional group-containing monomers in an organic solvent solution.
- the acrylate monomers used to make these polymers are normally alkyl acrylates of 4-17 carbon atoms, with 2-ethylhexylacrylate, butylacrylate and isooctylacrylate being preferred.
- Modifying monomers are typically included to alter the Tg of the polymer.
- modifying monomers are acrylates such as ethyl acrylate, vinyl acetate, and methyl methacrylate.
- the functional group-containing monomer provides sites for crosslinking.
- the functional group(s) will normally be carboxyl, hydroxyl, or combinations thereof.
- Monomers that provide such groups are acids, e.g. acrylic acid, and hydroxy-containing monomers such as hydroxyethyl acrylate. Examples of such solution polyacrylates are disclosed in the art. See, for instance, U.S. 5,393,529, the disclosure of which with respect to such copolymers is incorporated herein.
- Preferred copolymers are those of 2-ethylhexylacrylate, vinyl acetate, hydroxyethylacrylate, and glycidyl methacrylate.
- the drug component of the invention composition is a drug that has a reactive aromatic hydroxyl group.
- aromatic hydroxyl group intends a hydroxyl or hydroxyimino group that is attached directly to an annular carbon atom of a mono- or polycyclic aromatic moiety.
- Examples of such drugs are 17 ⁇ -estradiol, 17 ⁇ - estradiol, 17 ⁇ -estradiol cypionate, ethinyl estradiol, 3,17 ⁇ -estradiol dienanthate, 17 ⁇ - estradiolvalerate, 17-deacetyl norgestimate, and norgestimate.
- Other drugs may be included in the composition.
- the aromatic hydroxy-containing drug is estradiol
- progestogens and/or androgens may be included.
- the aromatic hydroxy- containing drug will usually constitute between about 0.5% and 10% by weight of the adhesive composition.
- the acrylate adhesive is crosslinked with sufficient aluminum acetylacetonate to significantly improve the cohesive strength and cold flow properties of the adhesive relative to those of the uncrosslinked adhesive.
- the crosslinking density should be low since high degrees of crosslinking may adversely affect the tack and pull adhesion or yield a nontacky product.
- the amount of aluminum acetylacetonate used is in the range of 0.1 to 1% by weight.
- the adhesive composition is crosslinked by mixing a solution of the polyacrylate, aluminum acetylacetonate, and drug in the desired proportions, causing the mixture to effect crosslinking, and then removing the solvent.
- the adhesive compositions of the invention may be used to form the matrix (drug reservoir) component of a transdermal patch or be used as a separate in-line adhesive layer. In either application, the composition defines the basal surface (i.e. the surface that contacts the skin) of the patch when the patch is in use. As indicated, when the composition is used to form the matrix, the drug is incorporated into the adhesive before crosslinking.
- compositions of this invention are unexpectedly substantially free of objectionable yellowing or other coloring.
- the use of other metallic acetylacetonates as crosslinking agents were found to produce colored compositions, or unacceptably high or low levels of crosslinking.
- the composition possesses acceptable cohesive strength and cold flow properties. Cohesive strength may be determined by a dynamic viscosity test. Cold flow may be observed visually. Normally the cold flow is observed after storage of the patch at elevated temperatures (e.g. 450C) for several months.
- Example 1 Preparation of Adhesive of Duro-Tak 2287. Aluminum Acetylacetonate and 17 J-estradiol. Duro-Tak 87-2287 is a solution polyacrylate available from National
- the cold flow properties of the assembly were tested by storing the assembly at 450C for 3 mos. No cold flow of the adhesive layer was observed. The adhesive layer of the patch remains uncolored after storage at 450C for 3 mos.
- patch assemblies were made from Duro-Tak 87-2287 and 3% estradiol without crosslinking agent. These assemblies exhibited poor dynamic viscosity (1.79E + 07). The adhesive remains clear after storage but cold flow was observed.
- Example 2 Comparison Preparations of Polyacrylate Crosslinked With Other Metallic Acetylacetonates and 17 ⁇ -estradiol.
- Duro-Tak 87-2516 is a solution polyacrylate available from National
- Example 1 Mixtures of Duro-Tak 87-2516 and 3% estradiol were prepared and cured as in Example 1. The mixture was cast into a release liner as in Example 1 and dried. The cured mixture and assembly were tested as in Example 1. The results were: dynamic viscosity, 5.00E + 07; E2 flux, 0.5 ⁇ 0.04 ⁇ g/cm 2 /hr; no cold flow; distinct yellow color.
Abstract
Non-yellowing organic solvent based pressure sensitive acrylate adhesives that have good cohesive strength and cold flow properties and are useful in fabricating transdermal drug delivery patches are made from an organic solvent based pressure sensitive acrylate adhesive cross-linked with aluminum acetylacetonate and combined with a drug, such as estradiol, that has a reactive aromatic hydroxyl group.
Description
PRESSURE SENSITIVE ACRYLATE ADHESIVE COMPOSITION CROSSLINKED WITH ALUMINUM ACETYLACETONATE AND CONTAINING A DRUG HAVING A REACTIVE AROMATIC HYDROXYL GROUP
Description
Technical Field
The present invention relates to transdermal drug delivery patches. More particularly it concerns a matrix type transdermal drug delivery patch whose matrix comprises a mixture of a pressure sensitive acrylate adhesive crosslinked with aluminum acetylacetonate and a drug, such as estradiol, which has a reactive aromatic hydroxyl group.
Background
Transdermal drug delivery patches normally include a backing layer that forms the outer face of the patch, a drug reservoir underlying the backing layer, and means to affix the patch to the skin. The drug reservoir may be a liquid solution or suspension of the drug or a solid matrix of a drug-carrier mixture. The carrier of the solid matrix may be an adhesive or have nonadhesive properties. If it is adhesive, the matrix may serve as the means for affixing the patch to the skin. If it is not adhesive, an in-line adhesive layer may underlie the matrix for affixing the patch to the skin. If the reservoir is a liquid, the patch will often include a drug-permeable membrane that underlies the reservoir and an in-line adhesive layer that underlies the membrane. Pressure sensitive adhesives are often used as the adhesive in the above- described patches. Pressure sensitive adhesives are used either as the carrier of the drug-containing matrix or as a separate in-line adhesive layer. In either instance the pressure sensitive adhesive will be admixed with drug.
Solution polyacrylate adhesives are one type of pressure sensitive adhesive that are used in transdermal drug delivery patches. Solution polyacrylates are made by copolymerizing one or more acrylate monomers, a modifying monomer and a monomer containing functional groups in a solution of an organic solvent. 2-Ethylhexylacrylate, butylacrylate and isooctylacrylate are commonly used as the acrylate monomer. The polyacrylate may be crosslinked on uncrosslinked. Crosslinked acrylate adhesives generally have better cohesive strength and resistance to cold flow than uncrosslinked acrylate adhesives. Increased cohesive strength is desirable in transdermal uses of acrylates to reduce the mass transfer of adhesive to the skin when the patch is removed. Resistance to cold flow is desirable to prevent the adhesive from oozing from the patch during storage or wear. Accordingly, crosslinked solution polyacrylates are preferred.
U.S. 5,393,529 describes an adhesive matrix type transdermal patch for delivering estradiol or estradiol esters. The adhesive of the matrix may be a crosslinked or uncrosslinked solution polyacrylate containing a water-swellable polymer.
Aluminum acetylacetonate is included in a list of possible agents for crosslinking the polyacrylate.
U.S. 5,292,951 describes estrogen-containing gels for topical application. The gels are comprised of estrogen, crosslinked acrylate polymers and relatively large amounts of a fat or oil that serves as an estrogen solubilizer.
Applicants have found that the selection of crosslinking agent is critical to preparing adhesive compositions of estradiol or other drugs that have a reactive aromatic hydroxyl group that will not develop an objectionable color and have the desired cohesive strength and cold flow properties discussed above. Accordingly, the present invention provides an adhesive composition comprising a crosslinked pressure sensitive acrylate adhesive mixed with an aromatic hydroxy-containing drug that does not develop objectionable color and has good cohesive strength and cold flow properties.
Disclosure of the Invention
One aspect of the invention is a pressure sensitive adhesive composition useful in a transdermal drug delivery patch comprising a mixture of: a) a drug having a reactive aromatic hydroxyl group; and b) an aluminum acetylacetonate crosslinked solution polyacrylate pressure sensitive adhesive.
Another aspect of this invention is a transdermal drug delivery patch in the form of a laminated composite comprising:
(a) a backing layer that forms the top surface of the patch; and (b) a matrix layer underlying the backing layer that comprises:
(i) a drug having a reactive aromatic hydroxyl group; and (ii) an aluminum acetylacetonate crosslinked acrylate pressure sensitive adhesive.
Modes for Carrying Out the Invention
The pressure sensitive adhesive component of the invention compositions and patches is a solution polyacrylate. Such polyacrylates are made by copolymerizing one or more main acrylate monomers ("acrylate" is intended to include both acrylates and methacrylates), one or more modifying monomers, and one or more functional group-containing monomers in an organic solvent solution. The acrylate monomers used to make these polymers are normally alkyl acrylates of 4-17 carbon atoms, with 2-ethylhexylacrylate, butylacrylate and isooctylacrylate being preferred. Modifying monomers are typically included to alter the Tg of the polymer. Examples of modifying monomers are acrylates such as ethyl acrylate, vinyl acetate, and methyl methacrylate. The functional group-containing monomer provides sites for crosslinking. In the polyacrylate of the present invention, the functional group(s) will normally be carboxyl, hydroxyl, or combinations thereof. Monomers that provide such groups are acids, e.g. acrylic acid, and hydroxy-containing monomers such as hydroxyethyl acrylate. Examples of such solution polyacrylates are disclosed in the art. See, for instance, U.S. 5,393,529, the disclosure of which with respect to such
copolymers is incorporated herein. Preferred copolymers are those of 2-ethylhexylacrylate, vinyl acetate, hydroxyethylacrylate, and glycidyl methacrylate. The drug component of the invention composition is a drug that has a reactive aromatic hydroxyl group. The term "aromatic hydroxyl group" intends a hydroxyl or hydroxyimino group that is attached directly to an annular carbon atom of a mono- or polycyclic aromatic moiety. Examples of such drugs are 17 β-estradiol, 17 α- estradiol, 17 β-estradiol cypionate, ethinyl estradiol, 3,17 β-estradiol dienanthate, 17β- estradiolvalerate, 17-deacetyl norgestimate, and norgestimate. Other drugs may be included in the composition. For instance when the aromatic hydroxy-containing drug is estradiol, progestogens and/or androgens may be included. The aromatic hydroxy- containing drug will usually constitute between about 0.5% and 10% by weight of the adhesive composition.
According to the present invention the acrylate adhesive is crosslinked with sufficient aluminum acetylacetonate to significantly improve the cohesive strength and cold flow properties of the adhesive relative to those of the uncrosslinked adhesive. The crosslinking density should be low since high degrees of crosslinking may adversely affect the tack and pull adhesion or yield a nontacky product. Normally the amount of aluminum acetylacetonate used is in the range of 0.1 to 1% by weight. The adhesive composition is crosslinked by mixing a solution of the polyacrylate, aluminum acetylacetonate, and drug in the desired proportions, causing the mixture to effect crosslinking, and then removing the solvent. Examples of solvents that may be used are ethylacetate, ethanol, methanol, toluene, isopropyl alcohol and heptane. The curing will normally be carried out at 50 to 1500C for 1 to 20 minutes. As indicated above, the adhesive compositions of the invention may be used to form the matrix (drug reservoir) component of a transdermal patch or be used as a separate in-line adhesive layer. In either application, the composition defines the basal surface (i.e. the surface that contacts the skin) of the patch when the patch is in use. As indicated, when the composition is used to form the matrix, the drug is incorporated into the adhesive before crosslinking. When the composition forms an in- line basal adhesive layer, the drug may be incorporated into the layer either before crosslinking or by equilibration after the patch has been assembled.
The compositions of this invention are unexpectedly substantially free of objectionable yellowing or other coloring. In this regard the use of other metallic acetylacetonates as crosslinking agents were found to produce colored compositions, or unacceptably high or low levels of crosslinking. In addition the composition possesses acceptable cohesive strength and cold flow properties. Cohesive strength may be determined by a dynamic viscosity test. Cold flow may be observed visually. Normally the cold flow is observed after storage of the patch at elevated temperatures (e.g. 450C) for several months.
The following examples further illustrate the invention. These examples are not intended to limit the invention in any manner. Unless indicated otherwise, stated percentages in the examples are by weight.
Example 1. Preparation of Adhesive of Duro-Tak 2287. Aluminum Acetylacetonate and 17 J-estradiol. Duro-Tak 87-2287 is a solution polyacrylate available from National
Starch and Chemical Company. It contains no crosslinking agent. (Its monomer composition is vinyl acetate; 2-ethylhexylacrylate; hydroxyethylacrylate; and glycidyl methacrylate.) It is available as a 50% by weight solids solution in ethyl acetate. A solution of Duro-Tak 87-2287 was mixed with 0.5% aluminum acetylacetonate, and 3% 17 β-estradiol. The mixture was cured at 900C for 2 min. and cast onto a release liner and the solvent was dried off. Cohesive strength tests were carried out on a sample of the mixture using a dynamic viscosity test. Its dynamic viscosity was 5.00E + 07. The dynamic viscosity is measured using Refleometrics Dynamic Spectrometer (RDS). The cured sample is placed between parallel plates in the RDS, and their dynamic viscosity measured at a frequency of 0.001 rad/sec.
Skin flux tests were carried out on the above-described Duro-Tak 87- 2287/estradiol and backing assembly according to the procedure described in Col. 7 of U.S. 5,252,334. The flux of drug from the assembly was 0.6 ± 0.1 μg/cm /hr.
The cold flow properties of the assembly were tested by storing the assembly at 450C for 3 mos. No cold flow of the adhesive layer was observed.
The adhesive layer of the patch remains uncolored after storage at 450C for 3 mos.
For comparison purposes, patch assemblies were made from Duro-Tak 87-2287 and 3% estradiol without crosslinking agent. These assemblies exhibited poor dynamic viscosity (1.79E + 07). The adhesive remains clear after storage but cold flow was observed.
Example 2. Comparison Preparations of Polyacrylate Crosslinked With Other Metallic Acetylacetonates and 17 β-estradiol. Duro-Tak 87-2516 is a solution polyacrylate available from National
Starch and Chemical Company. Its monomer composition is the same as Duro-Tak 87- 2287 but it contains polybutyl titanate crosslinker. It is available as a solution in a solvent system of ethylacetate/ethanol/heptane/methanol.
Mixtures of Duro-Tak 87-2516 and 3% estradiol were prepared and cured as in Example 1. The mixture was cast into a release liner as in Example 1 and dried. The cured mixture and assembly were tested as in Example 1. The results were: dynamic viscosity, 5.00E + 07; E2 flux, 0.5 ± 0.04 μg/cm2/hr; no cold flow; distinct yellow color.
Modification of the above-described modes for carrying out the invention that are obvious to those of skill in the fields of transdermal patch and/or pressure sensitive adhesives are intended to be within the scope of the following claims.
Claims
1. A pressure sensitive adhesive composition useful in a transdermal drug delivery patch comprising a mixture of: a) a drug having a reactive aromatic hydroxyl group; and b) an aluminum acetylacetonate crosslinked solution polyacrylate pressure sensitive adhesive.
2. The composition of claim 1 wherein the drug is 17 β-estradiol, an ester of 17 β-estradiol, α-estradiol, norgestimate, or 17-deacetyl norgestimate.
3. The composition of claim 2 wherein the acrylate adhesive is a copolymer of 2-ethylhexyl acrylate, vinyl acetate, hydroxyethyl acrylate and glycidyl methacrylate.
4. The composition of claim 1 wherein the drug constitutes 0.5% to 10%) by weight of the composition, and the aluminum acetylacetonate constitutes 0.1 % to 1% by weight of the composition.
5. The composition of claim 3 wherein the drug constitute 0.5% to
10%) by weight of the composition, and the aluminum acetylacetonate constitutes 0.1 %> to 1% by weight of the composition.
6. A transdermal drug delivery patch in the form of a laminated composite comprising:
(a) a backing layer that forms the top surface of the patch; and
(b) a matrix layer underlying the backing layer that comprises: (i) a drug having a reactive aromatic hydroxyl group; and (ii) an aluminum acetylacetonate crosslinked acrylate pressure sensitive adhesive.
7. The patch of claim 6 wherein the drug is 17 β-estradiol, an ester of 17 β-estradiol, α-estradiol, norgestimate, or 17-deacetyl norgestimate.
8. The patch of claim 7 wherein the acrylate adhesive is a copolymer of 2-ethylhexyl acrylate, vinyl acetate, hydroxyethyl acrylate and glycidyl methacrylate.
9. The patch of claim 6 wherein the drug constitutes 0.5% to 10% by weight of the composition, and the aluminum acetylacetonate constitutes 0.1 % to
1% by weight of the composition.
10. The patch of claim 8 wherein the drug constitute 0.5% to 10% by weight of the composition, and the aluminum acetylacetonate constitutes 0.1% to 1% by weight of the composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU60326/96A AU6032696A (en) | 1995-06-07 | 1996-06-03 | Pressure sensitive acrylate adhesive composition cross-linke d with aluminum acetylacetonate and containing a drug having a reactive aromatic hydroxyl group |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48429495A | 1995-06-07 | 1995-06-07 | |
| US08/484,294 | 1995-06-07 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1996040087A2 true WO1996040087A2 (en) | 1996-12-19 |
| WO1996040087A3 WO1996040087A3 (en) | 1997-01-30 |
Family
ID=23923554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1996/008492 WO1996040087A2 (en) | 1995-06-07 | 1996-06-03 | Pressure sensitive acrylate adhesive composition cross-linked with aluminum acetylacetonate and containing a drug having a reactive aromatic hydroxyl group |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU6032696A (en) |
| WO (1) | WO1996040087A2 (en) |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0836506A1 (en) * | 1995-06-07 | 1998-04-22 | Cygnus, Inc. | Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen |
| WO2001049273A2 (en) * | 2000-01-07 | 2001-07-12 | Lts Lohmann Therapie-Systeme Ag | Pharmaceutical composition for transdermally administering hormones with an additive that enhances permeation |
| WO2001092344A2 (en) * | 2000-06-01 | 2001-12-06 | Kraton Polymers Research, B.V. | Compositions comprising a functionalized block copolymer crosslinked with aluminum acetylacetonate |
| US6436433B1 (en) * | 1997-02-21 | 2002-08-20 | Lts Lohmann Therapie-Systeme Ag | Transdermal or topical plaster system with a polyacrylate matrix with improved physical properties |
| DE10157745A1 (en) * | 2001-11-24 | 2003-06-26 | Hf Arzneimittelforsch Gmbh | Transdermal therapeutic system for the administration of 17alpha-estradiol |
| US6653408B1 (en) | 2002-11-21 | 2003-11-25 | Kraton Polymers U.S. Llc | Compositions comprising a functionalized block copolymer crosslinked with aluminum acetylacetonate |
| JP2006528144A (en) * | 2003-07-23 | 2006-12-14 | エルテーエス ローマン テラピー−ジステーメ アーゲー | Transdermal therapeutic system containing pramipexole active agent |
| US7576226B2 (en) | 2003-06-30 | 2009-08-18 | Richter Gedeon Vegyeszeti Gyar Rt. | Process of making isomers of norelgestromin and methods using the same |
| WO2018022818A1 (en) | 2016-07-27 | 2018-02-01 | Corium International, Inc. | Memantine transdermal delivery systems |
| US9993466B2 (en) | 2016-07-27 | 2018-06-12 | Corium International, Inc. | Donepezil transdermal delivery system |
| US10016372B2 (en) | 2016-07-27 | 2018-07-10 | Corium International, Inc. | Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery |
| US10251844B2 (en) | 1998-03-30 | 2019-04-09 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system and method of use thereof for treating parkinsonism |
| US10759076B2 (en) | 2014-07-04 | 2020-09-01 | Luye Pharma Ag | Device for the manufacture of pharmaceutical patches |
| US11173132B2 (en) | 2017-12-20 | 2021-11-16 | Corium, Inc. | Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point |
| US11541018B2 (en) | 2016-06-23 | 2023-01-03 | Corium, Llc | Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10234673B4 (en) | 2002-07-30 | 2007-08-16 | Schwarz Pharma Ag | Hot-melt TTS for the administration of rotigotine and process for its preparation, and use of rotigotine in the manufacture of a hot-melt TTS |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0435200A2 (en) * | 1989-12-28 | 1991-07-03 | Nitto Denko Corporation | Estrogen-containing gel preparation |
| US5204109A (en) * | 1989-12-28 | 1993-04-20 | Nitto Denko Corporation | Percutaneous gel preparation |
| US5240711A (en) * | 1989-11-29 | 1993-08-31 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Transdermal therapeutic system comprising as active component buprenorphine |
| US5298258A (en) * | 1989-12-28 | 1994-03-29 | Nitto Denko Corporation | Acrylic oily gel bioadhesive material and acrylic oily gel preparation |
| US5306503A (en) * | 1990-06-25 | 1994-04-26 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Patch with a high content of softening ingredients |
-
1996
- 1996-06-03 WO PCT/US1996/008492 patent/WO1996040087A2/en active Application Filing
- 1996-06-03 AU AU60326/96A patent/AU6032696A/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5240711A (en) * | 1989-11-29 | 1993-08-31 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Transdermal therapeutic system comprising as active component buprenorphine |
| EP0435200A2 (en) * | 1989-12-28 | 1991-07-03 | Nitto Denko Corporation | Estrogen-containing gel preparation |
| US5204109A (en) * | 1989-12-28 | 1993-04-20 | Nitto Denko Corporation | Percutaneous gel preparation |
| US5298258A (en) * | 1989-12-28 | 1994-03-29 | Nitto Denko Corporation | Acrylic oily gel bioadhesive material and acrylic oily gel preparation |
| US5306503A (en) * | 1990-06-25 | 1994-04-26 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Patch with a high content of softening ingredients |
Cited By (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0836506A4 (en) * | 1995-06-07 | 1999-05-26 | Cygnus Therapeutic Systems | Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen |
| US5972377A (en) * | 1995-06-07 | 1999-10-26 | Cygnus, Inc. | Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen |
| US6071531A (en) * | 1995-06-07 | 2000-06-06 | Ortho-Mcneil Pharmaceutical, Inc. | Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen |
| EP0836506A1 (en) * | 1995-06-07 | 1998-04-22 | Cygnus, Inc. | Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen |
| US6436433B1 (en) * | 1997-02-21 | 2002-08-20 | Lts Lohmann Therapie-Systeme Ag | Transdermal or topical plaster system with a polyacrylate matrix with improved physical properties |
| US10322093B2 (en) | 1998-03-30 | 2019-06-18 | Ucb Biopharma Sprl | Method for producing a transdermal therapeutic system which contains a D2 agonist |
| US10251844B2 (en) | 1998-03-30 | 2019-04-09 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system and method of use thereof for treating parkinsonism |
| WO2001049273A3 (en) * | 2000-01-07 | 2002-05-23 | Lohmann Therapie Syst Lts | Pharmaceutical composition for transdermally administering hormones with an additive that enhances permeation |
| WO2001049273A2 (en) * | 2000-01-07 | 2001-07-12 | Lts Lohmann Therapie-Systeme Ag | Pharmaceutical composition for transdermally administering hormones with an additive that enhances permeation |
| WO2001092344A3 (en) * | 2000-06-01 | 2002-06-20 | Kraton Polymers Res Bv | Compositions comprising a functionalized block copolymer crosslinked with aluminum acetylacetonate |
| WO2001092344A2 (en) * | 2000-06-01 | 2001-12-06 | Kraton Polymers Research, B.V. | Compositions comprising a functionalized block copolymer crosslinked with aluminum acetylacetonate |
| DE10157745A1 (en) * | 2001-11-24 | 2003-06-26 | Hf Arzneimittelforsch Gmbh | Transdermal therapeutic system for the administration of 17alpha-estradiol |
| US6653408B1 (en) | 2002-11-21 | 2003-11-25 | Kraton Polymers U.S. Llc | Compositions comprising a functionalized block copolymer crosslinked with aluminum acetylacetonate |
| US7576226B2 (en) | 2003-06-30 | 2009-08-18 | Richter Gedeon Vegyeszeti Gyar Rt. | Process of making isomers of norelgestromin and methods using the same |
| US7816546B2 (en) | 2003-06-30 | 2010-10-19 | Richter Gedeon Vegyeszeti Gyar Rt. | Process for the synthesis of high purity d-(17α)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-oxime |
| JP2006528144A (en) * | 2003-07-23 | 2006-12-14 | エルテーエス ローマン テラピー−ジステーメ アーゲー | Transdermal therapeutic system containing pramipexole active agent |
| JP4925823B2 (en) * | 2003-07-23 | 2012-05-09 | エルテーエス ローマン テラピー−ジステーメ アーゲー | Transdermal therapeutic system containing pramipexole active agent |
| US10759076B2 (en) | 2014-07-04 | 2020-09-01 | Luye Pharma Ag | Device for the manufacture of pharmaceutical patches |
| US11541018B2 (en) | 2016-06-23 | 2023-01-03 | Corium, Llc | Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent |
| US9993466B2 (en) | 2016-07-27 | 2018-06-12 | Corium International, Inc. | Donepezil transdermal delivery system |
| US10307379B2 (en) | 2016-07-27 | 2019-06-04 | Corium, Inc. | Donepezil transdermal delivery system |
| US10300025B2 (en) | 2016-07-27 | 2019-05-28 | Corium, Inc. | Donepezil transdermal delivery system |
| US10016372B2 (en) | 2016-07-27 | 2018-07-10 | Corium International, Inc. | Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery |
| US10945968B2 (en) | 2016-07-27 | 2021-03-16 | Corium, Inc. | Memantine transdermal delivery systems |
| US11103463B2 (en) | 2016-07-27 | 2021-08-31 | Corium, Inc. | Methods for treating alzheimer's disease with donepezil transdermal system |
| WO2018022818A1 (en) | 2016-07-27 | 2018-02-01 | Corium International, Inc. | Memantine transdermal delivery systems |
| US11173132B2 (en) | 2017-12-20 | 2021-11-16 | Corium, Inc. | Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1996040087A3 (en) | 1997-01-30 |
| AU6032696A (en) | 1996-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2222133C (en) | Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen | |
| US5693335A (en) | Skin permeation enhancer composition for use with sex steroids | |
| WO1996040087A2 (en) | Pressure sensitive acrylate adhesive composition cross-linked with aluminum acetylacetonate and containing a drug having a reactive aromatic hydroxyl group | |
| CA2198390C (en) | Matrix for transdermal drug delivery | |
| DE10141652B4 (en) | Transdermal therapeutic system based on polyacrylate pressure-sensitive adhesives without functional groups and its use | |
| US6521250B2 (en) | Transdermal therapeutic system containing estradiol | |
| KR100677840B1 (en) | Transdermal therapeutic system comprising the active ingredient oxybutynin | |
| AU735944B2 (en) | Transdermal device for the delivery of testosterone | |
| US7976865B2 (en) | Medical tape preparation | |
| KR100373451B1 (en) | Estradiol Containing Patch | |
| JP2000514695A (en) | Transdermal drug delivery matrix for co-administration of estradiol and other steroids | |
| US6899894B1 (en) | Transdermal therapeutic system containing hormones and crystallization inhibitors | |
| JPH07330609A (en) | Endermic matrix system based on styrene-isoprene-styrene copolymer to be used for dozing estrogen and/or progestogen | |
| AU683017B2 (en) | Dexpanthenol-containing plaster for the transdermal application of steroid hormones | |
| IE921863A1 (en) | Nitroglycerine-plaster and process for its manufacture | |
| US6077527A (en) | Enhancer tolerant pressure sensitive adhesives for transdermal drug delivery | |
| JP3361674B2 (en) | Medical adhesive composition | |
| CA2233162A1 (en) | Transdermal matrix system | |
| WO1999066907A1 (en) | Transdermal therapeutic system containing hormones and crystallization inhibitors | |
| MXPA99007771A (en) | Transdermal device for the delivery of testosterone | |
| MXPA99006419A (en) | Transdermal, hormone-delivering therapeutic system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML |
|
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase in: |
Ref country code: CA |